How new leaders build — or lose — trust over time
Research from Olin Business School found that employees’ initial expectations for a new leader were a strong indicator of how trust levels would change over time. The higher the initial level of follower expectations, the steeper the resulting decline in trust.
Ideas matter—let’s create more
The director of WashU’s Skandalaris Center for Intrdisciplinary Innovation & Entrepreneurship, Il Luscri, talks about ideas and why we should create more of them.
‘The Downton Abbey Effect’: Olin dean researches unions between British aristocrats, American heiresses
“Downton Abbey” and a BBC miniseries based on Edith Wharton’s novel “The Buccaneers” inspired Olin Dean Mark P. Taylor to examine a historical trend.
Alumni, staff earn Fulbright awards
Nine alumni of Washington University earned Fulbright awards to conduct research or teach English this academic year. The program recognizes talented students who are committed to promoting global collaboration and understanding through research and teaching.
Plunkonomics: How business scientists studied baseball’s beanings for workplace parallels
Three business scientists, including two at Olin Business School, pored over 20 seasons of Major League Baseball hit-batsman statistics to reach some intriguing data and conclusions with implications off the field and in the office.
Let nature of work dictate return-to-work plans
Hybrid work may be the future for many organizations post-pandemic, but there will be significant challenges to overcome — perhaps even more so than traditional in-person offices and fully remote work environments, say Olin Business School researchers.
WashU runs in the family
For the Glazers, family reunions look more like WashU Reunions.
A novel way to learn business
In the course “Morality and Markets,” students gain new perspectives on real-life business situations through fiction.
Preserving the Negro Leagues
Kevin Johnson has worked for more than a decade to compile statistics from the Negro Leagues, ultimately helping them secure some long-awaited Major League recognition.
Pfizer, Moderna absent; Cara Therapeutics, Square in as 2020-21 R&D winners
Pharmaceutical and biotechnology companies topped the 2021 RQ Top 50 list of the most innovative U.S. companies. The annual ranking identifies the smartest R&D spenders – those companies that both spend big (at least $100 million in R&D) and provide the greatest returns to shareholders from that investment.
View More Stories